Prescription medicine
Methocarbamol Brand names: Robaxin, Atmeksi, Tanlor; first approved as Robaxin-750
Methocarbamol (Robaxin) is a prescription medicine with an FDA approval on record since 1957. FDA's NDC Directory lists it from 65 generic labelers, and pharmacies paid $0.0395 per methocarbamol 500 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the methocarbamol FDA label on DailyMed (effective March 17, 2026, Oxford Pharmaceuticals, LLC); the NDA 11011 record on Drugs@FDA; every methocarbamol label on DailyMed.
Highlights of the record
FDA label of March 17, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageMethocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.
Forms and strengths
- 500 mg
- 750 mg
- 1000 mg
- 100 mg/ml
- 750 mg/5ml
- 1000 mg/10ml
Tablet; film-coated tablet; coated tablet; injection; injection (solution).
On the market
- Earliest approval on file
- July 16, 1957 Robaxin-750, Endo Operations; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 50 first October 22, 1974; 18 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 67 of which 65 under generic applications, 2 under brand applications, repackagers included
- Last listed patent
- October 9, 2044 Atmeksi oral suspension; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $0.0395 per tablet Methocarbamol 500 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 6 since 2013 2 Class I among all firms' recalls; latest March 21, 2025; 3 more by firms not listed as its makers
- FAERS reports
- 22,591 through July 30, 2026
What is methocarbamol used for?
From the label: indications and usageMethocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense skeletal muscles in man.
Conditions named in the indications of methocarbamol's FDA labels, with every medicine labeled for each:
From other methocarbamol labelsMuscle spasms and spasticity: INDICATIONS AND USAGE Methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.
FDA pharmacologic class: Muscle Relaxant.
Source: FDA drug label (Methocarbamol), Oxford Pharmaceuticals, LLC, effective March 17, 2026 (SPL set 06dc72a6-ef3a-425a-9194-a9d228093cc4), via openFDA; the full label on DailyMed
Is there a generic for methocarbamol (Robaxin)?
The FDA approved the first generic methocarbamol on October 22, 1974. 50 generic applications are approved; 18 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists methocarbamol from 65 labelers under a generic (ANDA) application and from 2 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists no patent for Robaxin solution; a patent listed only for Atmeksi oral suspension runs to October 9, 2044. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 1957 earliest approval on file
- 1974 first generic approved
- 2044 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for methocarbamol (Robaxin)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.0395 per Methocarbamol 500 mg tablet, up 6% from $0.0371 on October 8, 2025. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Methocarbamol 500 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Methocarbamol 1,000 mg tablet | Generic | $8.35 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $250.44 | n/a |
| Methocarbamol 500 mg tablet | Generic | $0.0395 per tablet | $1.18 | +6% |
| Methocarbamol 750 mg tablet | Generic | $0.0431 per tablet | $1.29 | -0.9% |
| Tanlor 1,000 mg tablet | Generic | $8.35 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $250.44 | n/a |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has methocarbamol been recalled?
The FDA's Enforcement Report lists 9 recalls naming methocarbamol since 2013: 2 Class I (the most serious), 5 Class II, 2 Class III; 2 still ongoing. 3 of them are by firms that FDA's NDC Directory does not list as a maker of methocarbamol and that hold no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| March 21, 2025 | Class II | Somerset Therapeutics Private Limited | Lack of Assurance of Sterility: Media fill with bacterial contamination |
| February 15, 2024 | Class I | Eugia US LLC | Presence of Particulate Matter |
| October 12, 2021 | Class I | Bryant Ranch Prepack, Inc. dba BRP Pharmaceuticals | Labeling: Label Error on Declared Strength; Bottles labeled as Methocarbamol 500 mg Tablets actually contain Methocarbamol 750 mg Tablets |
| March 15, 2021 | Class II | Cardinal Health Inc. | CGMP Deviations: Intermittent exposure to temperature excursion during storage. |
| May 26, 2017 | Class II | American Pharmaceutical Ingredients LLC not a listed maker | CGMP Deviations: Lack of quality assurance at the API manufacturer. |
| August 11, 2015 | Class III | Golden State Medical Supply Inc. | Presence of Foreign Substance: Presence of hair. |
| October 19, 2013 | Class II | Specialty Medicine Compounding Pharmacy not a listed maker | Lack of Assurance of Sterility: All unexpired sterile compounded human and veterinary products are being recalled because they were compounded in the same … |
| July 2, 2013 | Class II | Aidapak Services, LLC not a listed maker | Labeling: Label Mixup: METHOCARBAMOL, Tablet, 500 mg may have potentially been mislabeled as the following drug: LOSARTAN POTASSIUM, Tablet, 25 mg, NDC … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the methocarbamol label say about other medicines?
The methocarbamol label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Pyridostigmine | drug interactions | Methocarbamol may inhibit the effect of pyridostigmine bromide. |
Source: FDA drug label (Methocarbamol), Oxford Pharmaceuticals, LLC, effective March 17, 2026 (SPL set 06dc72a6-ef3a-425a-9194-a9d228093cc4), via openFDA; the full label on DailyMed
What do FAERS reports show for methocarbamol?
The FDA Adverse Event Reporting System holds 22,591 reports that list methocarbamol among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 1,740 are coded as a death and 6,803 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as methocarbamol?
9 other medicines are given the same way (oral) and in the same FDA class as methocarbamol or labeled mainly for the same use (muscle spasms and spasticity), the same class first. Muscle spasms and spasticity lists all 12 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Cyclobenzaprine | Muscle spasms and spasticity | 60 labelers | $0.0171 per tablet 10 mg tablet | No current entry |
| Metaxalone | Muscle spasms and spasticity | 33 labelers | $0.452 per tablet 800 mg tablet | No current entry |
| Carisoprodol | Muscle spasms and spasticity | 24 labelers | $0.0706 per tablet 350 mg tablet | No current entry |
| Chlorzoxazone | Muscle spasms and spasticity | 19 labelers | $0.210 per tablet 500 mg tablet | No current entry |
| Orphenadrine | Muscle spasms and spasticity | 14 labelers | $0.454 per tablet 100 mg tablet | No current entry |
| Aspirin and caffeine and orphenadrine | Muscle spasms and spasticity | 3 labelers | n/a | No current entry |
| Baclofen | Muscle spasms and spasticity | 52 labelers | $0.032 per tablet 10 mg tablet | No current entry |
| Tizanidine | Muscle spasms and spasticity | 51 labelers | $0.0331 per tablet 4 mg tablet | No current entry |
Every medicine labeled for the same conditions as methocarbamol
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does methocarbamol compare with medicines for the same use?
9 side-by-side pages set methocarbamol beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to methocarbamol
- 9 medicines for the same use
- Other muscle relaxants
- the pharmacologic class, with prices and generics
- Methocarbamol side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other